



Office de la Propriété

Intellectuelle  
du Canada

Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office

An agency of  
Industry Canada

CA 2455341 A1 2002/12/05

(21) 2 455 341

(12) DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION


(13) A1

(86) Date de dépôt PCT/PCT Filing Date: 2002/05/29  
(87) Date publication PCT/PCT Publication Date: 2002/12/05  
(85) Entrée phase nationale/National Entry: 2003/11/19  
(86) N° demande PCT/PCT Application No.: SE 2002/001031  
(87) N° publication PCT/PCT Publication No.: 2002/096912  
(30) Priorité/Priority: 2001/06/01 (60/295,206) US

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C07D 491/22, A61K 31/439, A61P 1/04,  
A61P 25/00  
(71) Demandeur/Applicant:  
ASTRAZENECA AB, SE  
(72) Inventeur/Inventor:  
PHILLIPS, EIFION, US  
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : NOUVEAU LIGAND POUR RECEPTEURS NICOTINIQUES DE L'ACETYLCHOLINE UTILISES EN  
THERAPIE

(54) Title: NOVEL LIGAND FOR NICOTINIC ACETYLCHOLINE RECEPTORS USEFUL IN THERAPY



(57) Abrégé/Abstract:

A compound having the formula (I): and any pharmaceutically-acceptable salts thereof, and their uses in therapy and compositions containing them.

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number  
WO 02/096912 A1

(51) International Patent Classification<sup>7</sup>: C07D 491/22, A61K 31/439, A61P 25/00, 1/04

(21) International Application Number: PCT/SE02/01031

(22) International Filing Date: 29 May 2002 (29.05.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/295,206 1 June 2001 (01.06.2001) US

(71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PHILLIPS, Eifion [GB/US]; AstraZeneca Wilmington, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/096912 A1



(I)

(54) Title: NOVEL LIGAND FOR NICOTINIC ACETYLCHOLINE RECEPTORS USEFUL IN THERAPY

(57) Abstract: A compound having the formula (I): and any pharmaceutically-acceptable salts thereof, and their uses in therapy and compositions containing them.

Novel ligand for nicotinic acetylcholine receptors useful in therapy

**Technical Field**

This invention relates to novel spiroazabicyclic heterocyclic amines or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy. A further object is to provide active 5 compounds which are potent ligands for nicotinic acetylcholine receptors (nAChR's).

**Background Of The Invention**

The use of compounds which bind nicotinic acetylcholine receptors in the treatment of a range of disorders involving reduced cholinergic function such as Alzheimer's disease, cognitive or attention disorders, anxiety, depression, smoking cessation, neuroprotection, 10 schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease has been discussed in McDonald et al. (1995) "Nicotinic Acetylcholine Receptors: Molecular Biology, Chemistry and Pharmacology", Chapter 5 in Annual Reports in Medicinal Chemistry, vol. 30, pp. 41-50, Academic Press Inc., San Diego, CA; and in Williams et al. (1994) "Neuronal Nicotinic Acetylcholine Receptors," Drug News & Perspectives, vol. 7, pp. 205-223.


15 US Patent 5,468,875 discloses N-alkylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl esters which are centrally active muscarinic agents useful in the treatment of Alzheimer's disease and other disorders.

N-(2-alkoxyphenyl)carbamic acid 1-azabicyclo[2.2.2]octan-3-yl esters are disclosed in Pharmazie, vol. 48, 465-466 (1993) along with their local anesthetic activity. N- 20 phenylcarbamic acid 1-azabicyclo[2.2.2]octan-3-yl esters substituted at the *ortho* position on the phenyl ring are described as local anaesthetics in *Acta Pharm. Suecica*, 7, 239-246 (1970). Furopyridines useful in controlling synaptic transmission are disclosed in WO 97/05139.

**Summary of the Invention**

The invention generally relates to a compound having the formula:

25




and any pharmaceutically-acceptable salts thereof, and their uses in therapy and compositions containing them.

**Disclosure Of The Invention**

One aspect of the invention is A compound having the formula:

5



and any pharmaceutically-acceptable salts thereof.

Another aspect of the invention relates to a pharmaceutical composition comprising a compound as described above, and a pharmaceutically-acceptable diluent or carrier.

10 Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment of prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor beneficial.

Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

15 Another aspect of the invention relates to the above pharmaceutical composition for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic 20 synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and for ulcerative colitis.

Another aspect of the invention relates to a use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor is beneficial.

25 Another aspect of the invention relates to a use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

Another aspect of the invention relates to the above use, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder.

5 Another aspect of the invention relates to the above use, wherein the disorder is anxiety, schizophrenia, or mania or manic depression.

Another aspect of the invention relates to the above use, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.

10 Another aspect of the invention relates to the use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and for ulcerative colitis.

15 Another aspect of the invention relates to a method of treatment or prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor is beneficial which comprises administering a therapeutically effective amount of a compound as described above.

Another aspect of the invention relates to a method of treatment or prophylaxis of psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound as described above.

20 Another aspect of the invention relates to the above method, wherein the disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, or Attention Deficit Hyperactivity Disorder.

25 Another aspect of the invention relates to the above method, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.

Another aspect of the invention relates to the above method, wherein the disorder is anxiety, schizophrenia or mania or manic depression.

30 Another aspect of the invention relates to a method of treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction, pain, and for ulcerative colitis which comprises administering a therapeutically effective amount of a compound as described above.

### Pharmaceutical Compositions

A further aspect of the invention relates to a pharmaceutical composition for treating or preventing a condition or disorder as exemplified below arising from dysfunction of nicotinic acetylcholine receptor neurotransmission in a mammal, preferably a human, comprising an amount of a compound of formula I, an enantiomer thereof or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and an inert pharmaceutically acceptable carrier.

For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.1 mg to about 20 mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5 mg to 1,400 mg, more preferably from 10 mg to 100 mg, and unit dosage forms suitable for oral administration comprise from 2 mg to 1,400 mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I, or an enantiomer thereof, and pharmaceutically acceptable salts thereof, may be used on their own or in the form of appropriate medicinal preparations for enteral or parenteral administration. According to a further aspect of the invention, there is provided a pharmaceutical composition including preferably less than 80% and more preferably less than 50% by weight of a compound of the invention in admixture with an inert pharmaceutically acceptable diluent or carrier.

Examples of diluents and carriers are:

- for tablets and dragees: lactose, starch, talc, stearic acid; for capsules: tartaric acid or lactose;
- for injectable solutions: water, alcohols, glycerin, vegetable oils; for suppositories: natural or hardened oils or waxes.

There is also provided a process for the preparation of such a pharmaceutical composition which comprises mixing the ingredients.

### Utility

A further aspect of the invention is the use of a compound according to the invention, an enantiomer thereof or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prophylaxis of one of the below mentioned diseases or

conditions; and a method of treatment or prophylaxis of one of the above mentioned diseases or conditions, which comprises administering a therapeutically effective amount of a compound according to the invention, or an enantiomer thereof or a pharmaceutically acceptable salt thereof, to a patient.

5 Compounds according to the invention are agonists of nicotinic acetylcholine receptors. While not being limited by theory, it is believed that agonists of the  $\alpha 7$  nAChR (nicotinic acetylcholine receptor) subtype should be useful in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, and have advantages over compounds which are or are also agonists of the  $\alpha 4$  nAChR subtype. Therefore, compounds  
10 which are selective for the  $\alpha 7$  nAChR subtype are preferred. The compounds of the invention are indicated as pharmaceuticals, in particular in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders. Examples of psychotic disorders include schizophrenia, mania and manic depression, and anxiety. Examples of intellectual impairment disorders include Alzheimer's disease, learning deficit, cognition deficit, attention deficit,  
15 memory loss, and Attention Deficit Hyperactivity Disorder. The compounds of the invention may also be useful as analgesics in the treatment of pain (including chronic pain) and in the treatment or prophylaxis of Parkinson's disease, Huntington's disease, Tourette's syndrome, and neurodegenerative disorders in which there is loss of cholinergic synapses. The compounds may further be indicated for the treatment or prophylaxis of jetlag, for use in  
20 inducing the cessation of smoking, and for the treatment or prophylaxis of nicotine addiction (including that resulting from exposure to products containing nicotine).

It is also believed that compounds according to the invention are useful in the treatment and prophylaxis of ulcerative colitis.

### Pharmacology

25 The pharmacological activity of the compounds of the invention may be measured in the tests set out below:

#### Test A - Assay for affinity at $\alpha 7$ nAChR subtype

30  $^{125}\text{I-}\alpha\text{-Bungarotoxin (BTX) binding to rat hippocampal membranes}$ . Rat hippocampi were homogenized in 20 volumes of cold homogenization buffer (HB: concentrations of constituents (mM): tris(hydroxymethyl)aminomethane 50;  $\text{MgCl}_2$  1;  $\text{NaCl}$  120;  $\text{KCl}$  5: pH 7.4). The homogenate was centrifuged for 5 minutes at 1000 g, the supernatant was saved and

the pellet re-extracted. The pooled supernatants were centrifuged for 20 minutes at 12000 g, washed, and resuspended in HB. Membranes (30–80 µg) were incubated with 5 nM [<sup>125</sup>I]α-BTX, 1 mg/mL BSA (bovine serum albumin), test drug, and either 2 mM CaCl<sub>2</sub> or 0.5 mM EGTA [ethylene glycol-bis(β-aminoethylether)] for 2 hours at 21°C, and then filtered and washed 4 times over Whatman glass fibre filters (thickness C) using a Brandel cell harvester. Pretreating the filters for 3 hours with 1% (BSA/0.01% PEI (polyethyleneimine) in water was critical for low filter blanks (0.07% of total counts per minute). Nonspecific binding was described by 100 µM (–)-nicotine, and specific binding was typically 75%.

#### Test B - Assay for affinity to the α4 nAChR subtype

[<sup>3</sup>H]-(-)-nicotine binding. Using a procedure modified from Martino-Barrows and Kellar (Mol Pharm (1987) 31:169-174), rat brain (cortex and hippocampus) was homogenized as in the [<sup>125</sup>I]α-BTX binding assay, centrifuged for 20 minutes at 12,000 x g, washed twice, and then resuspended in HB containing 100 µM diisopropyl fluorophosphate. After 20 minutes at 4°C, membranes (approximately 0.5 mg) were incubated with 3 nM [<sup>3</sup>H]-(-)-nicotine, test drug, 1 µM atropine, and either 2 mM CaCl<sub>2</sub> or 0.5 mM EGTA for 1 hour at 4°C, and then filtered over Whatman glass fibre filters (thickness C) (pretreated for 1 hour with 0.5% PEI) using a Brandel cell harvester. Nonspecific binding was described by 100 µM carbachol, and specific binding was typically 84%.

#### Binding data analysis for Tests A and B

IC<sub>50</sub> values and pseudo Hill coefficients (n<sub>H</sub>) were calculated using the non-linear curve fitting program ALLFIT (DeLean A, Munson P J and Rodbard D (1977) Am. J. Physiol., 235:E97-E102). Saturation curves were fitted to a one site model, using the non-linear regression program ENZFITTER (Leatherbarrow, R.J. (1987)), yielding K<sub>D</sub> values of 1.67 and 1.70 nM for the <sup>125</sup>I-α-BTX and [<sup>3</sup>H]-(-)-nicotine ligands respectively. K<sub>i</sub> values were estimated using the general Cheng-Prusoff equation:

$$K_i = [IC_{50}] / ((2 + ([ligand]/[K_D]))^{1/n} - 1)$$

where a value of n=1 was used whenever n<sub>H</sub><1.5 and a value of n=2 was used when n<sub>H</sub>≥1.5. Samples were assayed in triplicate and were typically ±5%. K<sub>i</sub> values were determined using 6 or more drug concentrations. The compounds of the invention are compounds with binding affinities (K<sub>i</sub>) of less than 1000 nM in either Test A or Test B, indicating that they are expected to have useful therapeutic activity.

The compounds of the invention have the advantage that they may be less toxic, be more efficacious, be longer acting, have a broader range of activity, be more potent, produce fewer side effects, are more easily absorbed or have other useful pharmacological properties.

### Examples

5 Commercial reagents were used without further purification. Mass spectra were recorded using either a Hewlett Packard 5988A or a MicroMass Quattro-1 Mass Spectrometer and are reported as m/z for the parent molecular ion with its relative intensity. Room temperature refers to 20–25°C.

For additional examples and precursors, see published application WO 99/03859.

10 **Example 1A**

5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

A solution of spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (100 mg, 0.462 mmol) and sodium acetate (410 mg, 5 mmol) in 50 % aqueous acetic acid (4mL) was heated to 60°C. Bromine (0.100 mL, 1.94 mmol) was added via a syringe over 10 minutes, and the 15 solution was then heated under reflux for 1 hour. The mixture was allowed to cool to ambient temperature, basified to pH >10 with sodium carbonate, and extracted with chloroform (3 x 15 mL). The combined extracts were dried ( $\text{MgSO}_4$ ), filtered, and evaporated under reduced pressure to give the title compound (110 mg, 0.37 mmol, 81 %) as an off-white solid: electrospray MS 295 ( $[\text{MH}]^+$ , with  $^{79}\text{Br}$ , 100), 297 (  $[\text{MH}]^+$ , with  $^{81}\text{Br}$ , 98).

20 **Example 1B**

(R)-(-)- 5'-Bromospiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

The enantiomer (R)-(-)-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (1.95 g, 9 mmol) treated in the same way as described in example 2A provided the title compound (1.77 g, 6 mmol, 67%) ( $[\alpha]^{23} = -45.5^\circ$  (c = 1, MeOH)).

25 **Example 2**


(2'R)-5'-(2-furanyl)spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine]

(2'R)-5'-bromo-spiro[1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine] (0.70 g, 2.37 mmol), 3-furylboronic acid (0.39 g, 3.5 mmol), tetrakis(triphenylphosphine)palladium (0) (131 mg, 0.11 mmol), and sodium carbonate (0.75 g, 7.1 mmol) were placed in a tube 30 under nitrogen. Water (3 ml), ethanol (3 ml) and tetrahydrofuran (12 ml) were added. The mixture was then heated at 70 °C and stirred under nitrogen for 24 h. The mixture was then evaporated under vacuum and the residue from evaporation was partitioned between dilute

aqueous sodium hydroxide and chloroform, the layers were separated, and the aqueous layer was further extracted with chloroform. The chloroform extract was dried (magnesium sulfate), filtered, and evaporated. The residue was purified by reverse phase HPLC on a Waters Novapak-HR C<sub>18</sub> Column using a gradient of 0-70% acetonitrile / water (each solvent containing 0.1% trifluoroacetic acid as a buffer) as the eluant. The product-containing fractions were evaporated, then the residue was dissolved in methanol. Excess concentrated hydrochloric acid was added, and the solution was evaporated to give the dihydrochloride salt of the title compound (489 mg) as a colourless solid; m.p. 223-225 °C (decomp.); m/z 283 (100%, MH<sup>+</sup>).

**CLAIMS**

1. A compound having the formula:



5

and any pharmaceutically-acceptable salts thereof.

2. A pharmaceutical composition comprising a compound as described above, and a pharmaceutically-acceptable diluent or carrier.

10 3. The pharmaceutical composition according to Claim 2 for use in the treatment of prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor beneficial.

4. The pharmaceutical composition according to Claim 2 for use in the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

15 5. The pharmaceutical composition according to Claim 2 for use in the treatment or prophylaxis of Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, or mania or manic depression Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of 20 smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and for ulcerative colitis.


6. Use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor is beneficial.

25 7. Use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of psychotic disorders or intellectual impairment disorders.

8. The use according to Claim 7, wherein the condition or disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Attention Deficit Hyperactivity Disorder.

-10-

9. The use according to Claim 7 wherein the disorder is anxiety, schizophrenia, or mania or manic depression.
10. The use as claimed in claim 7 wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.
11. Use of a compound as described above in the manufacture of a medicament for the treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, and for ulcerative colitis.
12. A method of treatment or prophylaxis of human diseases or conditions in which activation of the  $\alpha 7$  nicotinic receptor is beneficial which comprises administering a therapeutically effective amount of a compound as described above.
13. A method of treatment or prophylaxis of psychotic disorders or intellectual impairment disorders, which comprises administering a therapeutically effective amount of a compound as described above.
14. The method according to Claim 13, wherein the disorder is Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, or Attention Deficit Hyperactivity Disorder.
15. The method according to Claim 13, wherein the disorder is Parkinson's disease, Huntington's disease, Tourette's syndrome, or neurodegenerative disorders in which there is loss of cholinergic synapses.
16. The method according to Claim 13, wherein the disorder is anxiety, schizophrenia or mania or manic depression.
17. A method of treatment or prophylaxis of jetlag, cessation of smoking, nicotine addiction, pain, and for ulcerative colitis which comprises administering a therapeutically effective amount of a compound as described above.



(I)